BioSpace News Archive

The U.S. Food and Drug Administration is announcing draft guidance for industry on action levels for lead in processed foods that are intended for babies and children under two years of age, to help reduce potential health effects in this vulnerable population from dietary exposure to lead.

Radon Medical Imaging (Radon), a leading medical imaging equipment maintenance and repair services company, announced today that it has acquired Premier Imaging Medical Systems.

Essent Biologics™, a leading supplier of human-derived cell and scaffold materials, today announced availability of its Human Native Tissue-Derived Type I Atelocollagen for the cell and tissue engineering industry.

MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, provides a corporate update highlighting the progress, adjustments to clinical programs and key development milestones expected in 2023.

HOUSTON, Jan. 24, 2023 /PRNewswire/ -- Fabre-Kramer Pharmaceuticals announced today it received on January 20, 2023 acknowledgement and acceptance of its December 23, 2022 NDA Amendment for EXXUA (gepirone hydrochloride) extended release tablets for the treatment of Major Depressive Disorder (MDD).

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.73 per share of the company’s common stock for the second quarter of 2023.

Beyond Cancer, Ltd. announces entry into a sponsored research agreement with Stanford School of Medicine and the appointment of Frederick M. Dirbas, MD, Associate Professor of Surgery, Division of Surgical Oncology, Stanford School of Medicine and Mark D. Pegram, MD, the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology at the Stanford School of Medicine to the Beyond Cancer Scientific Advisory Board.

Precigen, Inc. (Nasdaq: PGEN) today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ immunotherapy in patients with recurrent respiratory papillomatosis (RRP).

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases characterized by high unmet medical needs, announced its provisional financial calendar for 2023.

Hyloris Pharmaceuticals SA announces that its partner AFT Pharmaceuticals has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals for Maxigesic® IV, a novel, dual mode-of-action non-opioid pain treatment delivered through intravenous infusion, in 9 European markets.